Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.
Price Target and Rating
Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Terms of Service apply. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams.
More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends. According to 5 analysts, the average rating for CLSD difference between yield and return stock is “Strong Buy.” The 12-month stock price forecast is $5.8, which is an increase of 582.35% from the latest price. Clearside Biomedical saw a increase in short interest during the month of August.
According to 5 stock analysts, the average 12-month stock price forecast for CLSD stock stock is $5.80, which predicts an increase of 582.35%. On average, analysts rate CLSD stock stock as a strong buy. After positive clinical trial data yesterday, a regulatory update on the company’s other trials keeps the momentum going. The technique has proven to be very useful for finding positive surprises.
Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians
Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. 5 brokerages have issued twelve-month price objectives for Clearside Biomedical’s shares. Their CLSD share price forecasts range from $4.00 to $8.00. On average, they expect the company’s stock price to reach $5.60 in the next twelve months. This suggests a possible upside of 558.8% from the stock’s current price.
- As an investor, you want to buy stocks with the highest probability of success.
- The scores are based on the trading styles of Value, Growth, and Momentum.
- High-growth stocks tend to represent the technology, healthcare, and communications sectors.
- Since then, CLSD stock has decreased by 24.1% and is now trading at $0.85.
As of August 31st, there was short interest totaling 263,400 shares, an increase of 20.2% from the August 15th total of 219,200 shares. Based on an average trading volume of 123,200 shares, the short-interest ratio is presently 2.1 days. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023
In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. The average analyst rating for CLSD stock from 5 stock analysts is “Strong Buy”. This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
Promising trial results helped trigger a short squeeze and sent the biotech’s shares soaring. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also https://1investing.in/ has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Shares of Clearside Biomedical Inc. were up 12% in midday trade Thursday in the company’s debut on the Nasdaq. Shares were trading at $7.85, above the company’s $7 issue price.
5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Clearside Biomedical in the last year. The consensus among Wall Street equities research analysts is that investors should “buy” CLSD shares. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.
There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Clearside Biomedical’s stock was trading at $1.12 at the start of the year. Since then, CLSD stock has decreased by 24.1% and is now trading at $0.85.
View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts. Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS.
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.